Subchondral bone or intra-articular injection of bone marrow concentrate mesenchymal stem cells in bilateral knee osteoarthritis: what better postpone knee arthroplasty at fifteen years? A randomized study

Hernigou, Philippe; Bouthors, Charlie; Bastard, Claire; Lachaniette, Charles Henri Flouzat; Rouard, Hélène; Dubory, Arnaud

doi:10.1007/s00264-020-04687-7

Cited by 65 publications

(47 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this manner, a practical regenerative approach for OA is to enhance the performance of the subchondral bone by introducing additional bone marrow derived MSCs, to maintain osteochondral tissue homeostasis and prevent further cartilage loss. Some exciting results from a series of clinical trials have just been released by Hernigou et al ( 2018 , 2020a , b ) ( Table 3 ), with clinical data of up to 15 years of follow-ups. Patients with different OA conditions (moderate to advanced OA, 60 cases; advanced OA, 140 cases; OA secondary to knee osteonecrosis related to corticosteroids, 30 cases) were recruited.…”

Section: Future Therapeutic Targetsmentioning

confidence: 99%

“…Delivery sites (subchondral bone vs . intraarticular) of MSCs are also of importance: 20% of the knees (12 in 60) in the subchondral implantation group underwent TKA at a mean of 14 years (range, 9–16 years), while 70% of the knees (42 in 60) in the intra-articular implantation group underwent TKA at a mean of 7 years (range, 3–14 years) (Hernigou et al, 2020a ).…”

Section: Future Therapeutic Targetsmentioning

confidence: 99%

“…From the patient inclusion criteria of subchondroplasty and the cell-based therapies ( Table 2 ), it is clear that regenerative therapies are the frontline choices to bone marrow lesions (Hernigou et al, 2020a ), osteochondral defects, and injuries (Brittberg et al, 1994 ; Wakitani et al, 2002 , 2007 ; Kuroda et al, 2007 ; Peterson et al, 2010 ; Jiang et al, 2016 ).…”

Section: Oa Subtypes and Therapeutic Targetsmentioning

confidence: 99%

Section: Regenerative Therapymentioning

confidence: 99%

See 3 more Smart Citations

Subchondral Bone Remodeling: A Therapeutic Target for Osteoarthritis

Zhu

Chan

Yung

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

There is emerging awareness that subchondral bone remodeling plays an important role in the development of osteoarthritis (OA). This review presents recent investigations on the cellular and molecular mechanism of subchondral bone remodeling, and summarizes the current interventions and potential therapeutic targets related to OA subchondral bone remodeling. The first part of this review covers key cells and molecular mediators involved in subchondral bone remodeling (osteoclasts, osteoblasts, osteocytes, bone extracellular matrix, vascularization, nerve innervation, and related signaling pathways). The second part of this review describes candidate treatments for OA subchondral bone remodeling, including the use of bone-acting reagents and the application of regenerative therapies. Currently available clinical OA therapies and known responses in subchondral bone remodeling are summarized as a basis for the investigation of potential therapeutic mediators.

show abstract

Section: Future Therapeutic Targetsmentioning

confidence: 99%

Section: Future Therapeutic Targetsmentioning

confidence: 99%

Section: Oa Subtypes and Therapeutic Targetsmentioning

confidence: 99%

Section: Regenerative Therapymentioning

confidence: 99%

See 2 more Smart Citations

Subchondral Bone Remodeling: A Therapeutic Target for Osteoarthritis

Zhu

Chan

Yung

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Gobbi et al [58] compared with microfracture with BMA in the treatment of OCLs and found that microfracture resulted in 65% normal IKDC at two years with decline to 27% at five years vs 100% normal at two years and no decline at five years for patients treated with BMA. These positive results were found when evaluating BMA in the treatment of knee osteoarthritis [59][60][61].…”

Section: Systemic Intravenous Stem Cell Transplantation In Orthopaedimentioning

confidence: 84%

Bone marrow in orthopaedics (part II): a three hundred and seventy million-year saga from the Devonian to the coronavirus disease 2019 pandemic—osteonecrosis; transplantation; “human chimera”; stem cells, bioreactors, and coronavirus disease

Hernigou

2020

International Orthopaedics (SICOT)

Self Cite

View full text Add to dashboard Cite

Purpose Three hundred seventy million years ago, bone marrow appeared in skeleton of a fish. More than one hundred years ago, the concept of bone marrow transplantation was proposed to treat human diseases. During the last five decades, this concept became a reality first in hematology and later for orthopaedic diseases. Material and methods These advances were possible due to the comprehension of the three major components of bone marrow: the fat part, the haematologic part, and the stroma part. Each part has a different history, but the three parts are linked in physiology as in history. Results During many centuries, bone marrow was considered just as food; however, one hundred years ago, the concept of bone marrow transplantation to treat humans was proposed by the French physician Brown-Séquard. During the last five decades, this concept became a reality first in haematology and later for orthopaedic diseases. Transferring what was known from experimental animal models to humans was met with many challenges, the atomic bomb research, and many deaths. Yet through the recognition and subsequent understanding of fundamental processes, medical resiliency, and the determination of a few pioneers, local bone marrow transplantation in orthopaedic surgery became a therapeutic option first for a limited number of diseases and patients. Over the last two decades, mesenchymal stromal cells (MSCs) have been the focus of intense research by acadaemia and industry due to their unique features. MSCs can be easily isolated and expanded through in vitro culture by taking full advantage of their self-renewing capacity. In addition, MSCs exert immunomodulatory effects and can be differentiated into various lineages, which makes them highly attractive for clinical applications in cell-based therapies. Conclusion In this review, we attempted to provide a historical overview of bone marrow history, MSC discovery, characterization, and the first clinical studies conducted. Keywords Bone marrow history. Stem cells. Osteonecrosis. Marrow transplantation. Tissue engineering What is the relation between a 370-million-year-old fish, osteonecrosis, "The Irish Iliad", the neurologist Brown-Séquard, the Milano Ossobucco, Einstein, Hiroshima, and tissue engineering in orthopaedic surgery? It is just bone marrow. After description of the bone marrow history in traumatology [1], this article is a short history of bone marrow

show abstract